Another clinical trial shows that, in pediatric DIPG patients, Nimotuzumab treatment was well-tolerated, and there was modest nimotuzumab activity in DIPG, which means that a small population of DIPG patients appear to benefit from anti-EGFR antibody treatment [66]. The gene discussed is EGFR; the disease is diffuse intrinsic pontine glioma.